20885-21-6

Basic information

• Product Name: 5-NITRO-2-METHYLTHIOPYRIDINE
• Synonyms: 3-Nitro-6-(methylthio)pyridine;2-(Methylthio)-5-nitropyridine
• CAS NO: 20885-21-6
• Molecular Formula: C₆H₆N₂O₂S
• Molecular Weight: 170.19
• Mol File: 20885-21-6.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 309.9 °C at 760 mmHg
• Flash Point: 141.2 °C
• Appearance: /
• Density: 1.35 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-NITRO-2-METHYLTHIOPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-NITRO-2-METHYLTHIOPYRIDINE(20885-21-6)
• EPA Substance Registry System: 5-NITRO-2-METHYLTHIOPYRIDINE(20885-21-6)

Safety Data

• Hazardous Substances Data: 20885-21-6(Hazardous Substances Data)

Usage

General Description

5-Nitro-2-methylthiopyridine is a chemical compound categorized under the group of organosulfur compounds. This specific chemical is characterized by the presence of a nitro group (-NO2) and a methylthio group (-SCH3) attached to a pyridine ring, which is a six-membered aromatic heterocycle with five carbon atoms and one nitrogen atom. Pyridine derivatives like 5-nitro-2-methylthiopyridine often display interesting chemical properties and potential applications in various fields. However, like many chemicals, it should be handled carefully due to potential hazards associated with its use, although its specific safety profile and applications may vary depending on the exact context.

Upstream product

• 186581-53-3 diazomethane 
• 2127-09-5 2-mercapto-5-nitropyridine 
• 74-88-4 methyl iodide 
• 4548-45-2 2-chloro-5-nitropyridine 
• 74-93-1 methylthiol 
• 4487-59-6 2-bromo-5-nitropyridine 
• 5188-07-8 sodium thiomethoxide 
• 77-78-1 dimethyl sulfate 
• 867-44-7 S-Methylisothiourea sulfate 

Downstream Products

• 29958-08-5 6-methylsulfanyl-pyridin-3-ylamine 
• 79134-11-5 3-Nitro-6-(methylsulfonyl)pyridine 
• 1198785-08-8 (6-methylsulfanylpyridin-3-yl)carbamic acid tert-butyl ester 
• 1293979-17-5 C₁₃H₁₀F₂N₂OS 
• 187143-22-2 6-(methylsulfonyl)pyridin-3-amine 
• 1198785-18-0 2-bromo-6-methanesulfonylpyridin-3-ylamine 
• 1198785-09-9 (6-methylsulfanyl-4-iodopyridin-3-yl)carbamic acid tert-butyl ester 
• 1198784-49-4 (R)-4-(4-chloro-2-methanesulfonylphenyl)-1,1,1-trifluoro-2-(5-methanesulfonyl-1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-4-methylpentan-2-ol 
• 1198785-50-0 {4-[(S)-6-(4-chloro-2-methanesulfonylphenyl)-4-hydroxy-6-methyl-4-trifluoromethylhept-1-ynyl]-6-methanesulfonylpyridin-3-yl}carbamic acid tert-butyl ester 

Relevant articles and documents

Cesium carbonate-promoted synthesis of aryl methyl sulfides using: S -methylisothiourea sulfate under transition-metal-free conditions

In the presence of cesium carbonate, an efficient synthesis of aryl methyl sulfides by the reactions of aryl halides with commercially available S-methylisothiourea sulfate is developed. This odourless and highly crystalline solid can be used as the subst

5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, fibrotic disorders, cartilage (chondral) defects, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, and neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

lndazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole-3- carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.